49. 全身性エリテマトーデス Systemic lupus erythematosus Clinical trials / Disease details
臨床試験数 : 946 / 薬物数 : 722 - (DrugBank : 186) / 標的遺伝子数 : 117 - 標的パスウェイ数 : 199
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02633163 (ClinicalTrials.gov) | October 26, 2018 | 15/12/2015 | Phase 2 Trial of Mesenchymal Stem Cells in Systemic Lupus Erythematosus (MiSLE) | A Phase II Controlled Trial of Allogeneic Mesenchymal Stem Cells for the Treatment of Refractory Lupus | Systemic Lupus Erythematosus | Drug: Low Dose Mesenchymal Stem Cells (MSCs);Drug: High Dose Mesenchymal Stem Cells (MSCs);Drug: Placebo Infusion | Medical University of South Carolina | NULL | Recruiting | 18 Years | 65 Years | All | 81 | Phase 2 | United States |
2 | NCT03171194 (ClinicalTrials.gov) | April 27, 2017 | 4/5/2017 | Pilot Trial of Mesenchymal Stem Cells for Systemic Lupus Erythematosus | A Phase I Safety Trial of Allogeneic Mesenchymal Stem Cells for Systemic Lupus Erythematosus | System; Lupus Erythematosus | Drug: Low Dose Mesenchymal Stem Cells (MSCs) | Medical University of South Carolina | NULL | Completed | 18 Years | 65 Years | All | 6 | Phase 1 | United States |